AstraZeneca

AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma
AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma
Pharmaceutical Business Review
AstraZeneca
Symbicort Turbohaler
asthma
mild asthma
Flag link:
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis
Fierce Pharma
AstraZeneca
Fasenra
severe asthma
asthma
clinical trials
Flag link:
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
Fierce Biotech
AstraZeneca
Avastin
anti-VEGF
cediranib
Flag link:
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
Endpoints
AstraZeneca
cediranib
ovarian cancer
Yale
PARP inhibitors
Flag link:
3 Top Diabetes Stocks to Watch in May
3 Top Diabetes Stocks to Watch in May
Motley Fool
diabetes
AstraZeneca
Eli Lilly
Medtronic
Flag link:
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Endpoints
Alzheimer's disease
drug development
aducanumab
Biogen
Eisai
BAN2401
Merck
Eli Lilly
AstraZeneca
Flag link:
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
BioSpace
AstraZeneca
Forty Seven
clinical trials
diffuse large B-cell lymphoma
Flag link:
Roxadustat safety analysis provokes more questions than answers
Roxadustat safety analysis provokes more questions than answers
EP Vantage
FibroGen
roxadustar
anemia
AstraZeneca
Flag link:
Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs
Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs
Fierce Pharma
gangrene
diabetes
JNJ
Invokana
AstraZeneca
Farxiga
Eli Lilly
Boehringer Ingelheim
Jardiance
Flag link:
AstraZeneca's share dilution gamble on Daiichi drug pays off
AstraZeneca's share dilution gamble on Daiichi drug pays off
Biopharma Dive
AstraZeneca
Daiichi Sankyo
trastuzumab deruxtecan
metastatic breast cancer
Flag link:
AZ and Daiichi to file new breast cancer drug after trial success
AZ and Daiichi to file new breast cancer drug after trial success
Pharmaforum
AstraZeneca
Daiichi Sankyo
trastuzumab deruxtecan
antibody-drug conjugate
Flag link:
Artificial Intelligence is Ramping up in Drug Development
Artificial Intelligence is Ramping up in Drug Development
BioSpace
AstraZeneca
drug development
artificial intelligence
BenevolentAI
Flag link:
Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises
Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises
Endpoints
AstraZeneca
Calquence
clinical trials
chronic lymphocytic leukemia
AbbVie
JNJ
Imbruvica
Flag link:
FDA approves AstraZeneca's triple combination therapy for type 2 diabetes
FDA approves AstraZeneca's triple combination therapy for type 2 diabetes
Healio
AstraZeneca
type 2 diabetes
FDA
Qternmet XR
Flag link:
AstraZeneca ups oncolytic virus activity with Transgene deal
AstraZeneca ups oncolytic virus activity with Transgene deal
Fierce Biotech
AstraZeneca
Transgene
oncolytic viruses
drug development
Flag link:
AZ researches kidney and lung drugs with BenevolentAI
AZ researches kidney and lung drugs with BenevolentAI
Pharmaforum
AstraZeneca
artificial intelligence
R&D
BenevolentAI
Flag link:
Lynparza on cusp of EU approval for advanced ovarian cancer
Lynparza on cusp of EU approval for advanced ovarian cancer
Pharmaforum
AstraZeneca
Lynparza
Europe
CHMP
ovarian cancer
Flag link:
Soriot sees progress in U.S.-China IP debate
Soriot sees progress in U.S.-China IP debate
BioCentury
China
AstraZeneca
Pascal Soriot
intellectual property
Flag link:
AstraZeneca dumps Amgen-partnered drug after midphase fail
AstraZeneca dumps Amgen-partnered drug after midphase fail
Fierce Biotech
AstraZeneca
Amgen
prezalumab
Sjöogren’s syndrome
Flag link:
Newer drugs fuel AstraZeneca quarterly sales beat
Newer drugs fuel AstraZeneca quarterly sales beat
Yahoo/Reuters
AstraZeneca
earnings
Flag link:

Pages